COYA THERAPEUTICS INC

Business Model and Scope

Coya is a clinical-stage biotechnology company developing therapies intended to improve the number or suppressive function of regulatory T cells, or Tregs. Tregs regulate inflammatory and autoimmune responses. The company has explored autologous Treg cell therapy, Treg-derived exosomes, and biologic combinations, but its current economic center is COYA 302, a co-pack combination of proprietary low-dose interleukin-2, called COYA 301, and CTLA4-Ig.

COYA 302 is being developed most concretely for amyotrophic lateral sclerosis, or ALS. The FDA accepted an investigational new drug application in August 2025, and dosing began in the randomized, double-blind, placebo-controlled Phase 2 ALSTARS trial in December 2025. An IND for frontotemporal dementia, or FTD, was accepted in January 2026. COYA 303, a preclinical combination of COYA 301 and a GLP-1 receptor agonist, and exosome research are earlier and less proven.

No Coya product was approved or sold at the cutoff. Coya performs and funds development, manages intellectual property and partners, and relies on contract research and manufacturing organizations, clinical sites, licensors, and collaborators. Collaboration revenue from Dr. Reddy's Laboratories is not product demand. The business is a portfolio of contingent rights and development obligations, not a commercial drug company.

Customers and Purchasing Decisions

If approved, the ultimate clinical customers are ALS, FTD, Alzheimer's, Parkinson's, or autoimmune-disease patients and the physicians treating them. They need a therapy that changes meaningful outcomes with tolerable safety and manageable administration. ALS patients face rapid functional decline and limited treatment options; that unmet need can support adoption, but it cannot lower the evidentiary threshold. Physicians will compare survival, function, adverse events, treatment burden, interactions, and confidence in the data.

Payers and health systems decide access and net economics. They can demand comparative evidence, restrict use, negotiate price, or require prior authorization. Existing therapies, supportive care, clinical trials, and competing mechanisms are substitutes. A biomarker effect or plausible immune mechanism creates scientific interest; it is not the outcome patients or payers purchase.

Before approval, Dr. Reddy's is Coya's most important commercial counterparty. It owns exclusive ALS commercialization rights in the United States, Canada, European Union, and United Kingdom under the development agreement and has rights in many other territories under a separate license. Coya retains specified territories and non-ALS opportunities. Asset licensors such as ARScience and Houston Methodist are suppliers of essential intellectual property. Their rights, milestones, and royalties constrain how much of any eventual product value Coya can retain.

Profit Creation and Value Capture

Coya has no current product-profit mechanism. Durable profit would require COYA 302 or another candidate to produce convincing controlled clinical data, complete larger trials, obtain regulatory approval, achieve reimbursement and physician adoption, and generate net sales above manufacturing, distribution, medical, regulatory, and partner claims. Each step is conditional, and development spending is lost if a program fails.

The Dr. Reddy's agreement provides nearer-term funding and risk sharing. Coya received a $7.5 million upfront payment in January 2024, $4.2 million after the ALS IND acceptance, and $4.2 million after first Phase 2 dosing. The agreement calls for up to about $40 million of development milestones and $677.3 million of sales milestones in specified territories if all conditions are met, plus low-to-mid-teens royalties on net sales before royalties owed under earlier licenses. Large headline milestones are not receivables; most require outcomes that have not occurred.

In 2025, collaboration revenue was $7.9 million, including $6.7 million of license revenue tied to milestones and $1.2 million of research services. R&D expense was $16.7 million, acquired in-process R&D was $2.3 million, and general and administrative expense was $11.4 million. The company lost $21.2 million and used $10.7 million in operations. Collaboration accounting can recognize a milestone or allocated license value well before a medicine produces recurring cash profit.

Value is divided widely. Patients and health systems capture clinical benefit. Dr. Reddy's retains commercialization control and economics in major ALS territories. ARScience, Dr. Reddy's as abatacept licensor, and Houston Methodist receive milestones or royalties. Contract manufacturers, research organizations, investigators, employees, and regulators are funded before shareholders. Coya shareholders retain a residual claim weakened by future financing dilution and upstream royalties. Profit per share therefore depends on clinical probability, retained territory and royalty economics, and capital required to reach the next decisive result.

Industry Structure and Capital Cycle

Coya competes in ALS and neuroinflammation against approved therapies, symptomatic care, and clinical-stage programs from large and small companies. The filing identifies ALS competitors including Ionis with Biogen, Neurizon, Alchemab with Eli Lilly, Athira, NeuroSense, Amylyx, MediciNova, and Clene. Treg-directed biologics using altered or sustained IL-2 approaches are being developed by companies including Amgen, Nektar, Merck, and Xencor. Competitors can target the same biology, a different inflammatory pathway, protein aggregation, genetics, or neuronal survival.

Suppliers possess substantial bargaining power. Specialized contract manufacturers must produce consistent biologics and a co-pack combination. Clinical sites and scarce ALS patients determine enrollment speed. Licensors control patents and know-how. Dr. Reddy's supplies the abatacept biosimilar component and, if the joint steering committee cannot resolve a dispute, has final decision authority subject to limits. Regulators decide whether evidence and manufacturing support progression.

Entry requires scientific credibility, patents or licenses, manufacturing, clinical expertise, and funding, but abundant biotechnology capital periodically finances many overlapping programs. Positive early data attract investment and competitors; later failures close programs and strand specialized spending. When capital markets weaken, small issuers must issue equity on poor terms or delay trials. A partner can reduce funding risk while capturing a large portion of commercial value.

The clinical capital cycle is long. Spending rises from preclinical work through Phase 1, controlled Phase 2, pivotal trials, validation, and launch before product cash arrives. Coya's small, open-label investigator studies may improve trial design, but noisy early observations can lead to overinvestment. The ALSTARS randomized trial is the first more rigorous test of the central commercial thesis.

Sources and Durability of Competitive Advantage

Coya's proposed advantage is mechanistic: low-dose IL-2 is intended to enhance anti-inflammatory Tregs, while CTLA4-Ig suppresses pro-inflammatory monocyte and macrophage signaling. A combination could address more than one inflammatory pathway and use COYA 301 as a backbone for additional combinations. Earlier autologous Treg work supplied biological learning and biomarkers without requiring Coya to commercialize a complex personalized cell therapy.

That mechanism is not yet an economic advantage. COYA 302 uses components and pathways known to competitors, and a co-pack may be easier to manufacture than cell therapy but does not itself prove efficacy or exclusivity. Patents and licensed know-how can delay direct copying; alternative molecules or mechanisms can bypass them. Dr. Reddy's development and manufacturing capabilities may reduce execution risk while also transferring bargaining power and commercialization control.

The strongest evidence would be a clinically meaningful, reproducible benefit in a controlled trial, linked to a defensible dose and biomarker response. At the cutoff, that evidence did not exist. The FDA's 2024 request for additional non-clinical data before the planned ALS study is contrary evidence to a frictionless development path, even though the IND was later accepted. Calling COYA 302 a "pipeline in a product" expresses strategic ambition, not diversification: failure of the common backbone could impair several indications at once.

Operating System and Strategic Trade-offs

Coya uses a virtual, partner-dependent model. Internal management selects programs, maintains licenses, designs development, oversees vendors, raises capital, and manages regulatory submissions. Houston Methodist supplies scientific relationships and licensed know-how. Contract research organizations, laboratories, manufacturers, and trial sites perform much of the physical work. This limits fixed infrastructure but creates dependence on suppliers whose priorities and quality Coya does not fully control.

COYA 302 coordination is unusually important because low-dose IL-2 and CTLA4-Ig must be sourced, manufactured, packaged, documented, and administered consistently. Technology transfer and scale-up begin before efficacy is known because later trials require reliable material. Spending too early wastes capital if the trial fails; spending too late delays development if data are favorable. The January 2026 financing, including $10 million from a Dr. Reddy's affiliate, was intended partly to accelerate low-dose IL-2 technology transfer and manufacturing readiness.

The Dr. Reddy's joint steering committee aligns expertise but divides control. Coya bears specified development obligations, while its partner controls major-territory commercialization and holds final authority after unresolved escalation on certain matters. The operating model works only if Coya can preserve trial quality, vendor oversight, intellectual property, and strategic discipline with limited resources. A single manufacturing, enrollment, safety, or partner dispute can delay the whole lead program.

Financial Resilience

Coya held $46.8 million of cash and cash equivalents at December 31, 2025 and raised $11.1 million of gross proceeds in January 2026. Management expected those resources to fund operating and capital needs into the second half of 2027 and for at least one year after issuance of the financial statements. The company had no product revenue and an accumulated deficit of $62.0 million.

Cash use in operations was $10.7 million in 2025, but that figure benefited from collaboration receipts and precedes the full cost of ongoing Phase 2 work, manufacturing scale-up, and any later-stage trial. R&D increased from $11.9 million in 2024 to $16.7 million in 2025. Cash runway is therefore an estimate conditional on enrollment, vendor, manufacturing, and program decisions; it is not enough to fund commercialization or necessarily a registrational program.

The balance sheet has little conventional debt stress, but equity dependence is itself financial risk. An adverse clinical result could close access to capital or require severe dilution. The company issued shares for net proceeds of $20.3 million in October 2025 after raising equity in 2024 and 2023. Dr. Reddy's funding extends runway but is milestone-dependent and cedes economics. In a severe scenario, Coya would need to narrow the pipeline, delay work, renegotiate a partnership, or issue equity rather than rely on internally generated cash.

Capital Allocation and Shareholder Outcomes

The appropriate priority is generating decisive evidence for COYA 302 while preserving enough liquidity to interpret and act on the result. Funding many indications before the ALS trial clarifies efficacy would multiply common-mechanism risk. COYA 303 and exosome work may create options, but each competes with manufacturing, clinical, and management resources. Partnerships or grants are more appropriate where Coya lacks capital to advance an early program independently.

Licensing reduced required commercial infrastructure and supplied non-dilutive cash, but the contract distributes value before shareholders. The June 2024 amendment paid Coya $3.9 million while eliminating Dr. Reddy's obligation to pay the first $6.0 million of royalties that otherwise would have been due. That trade improved near-term liquidity at the expense of contingent future receipts. Upstream obligations include single-digit royalties to Dr. Reddy's on licensed input economics, low-to-mid-single-digit royalties to ARScience, and potentially high-single-digit to low-double-digit royalties to Houston Methodist for applicable licensed products.

Stock-based compensation was $4.3 million in 2025, material beside the $21.2 million net loss, and unrecognized option compensation was $5.1 million. Equity offerings increase the denominator while funding value-creating experiments. Common shareholders benefit only if probability-adjusted retained program value grows faster than cash burn, royalties, option dilution, and new shares. Milestone headlines and a larger indication list do not meet that test.

Legal and Regulatory Exposure

FDA acceptance of an IND authorizes a trial; it is not approval or endorsement of efficacy. The FDA can impose a clinical hold, require new non-clinical or manufacturing work, reject endpoints, demand additional trials, or deny a marketing application. Trial safety, informed consent, data integrity, adverse-event reporting, and good clinical and manufacturing practices are continuing obligations. A combination product can require evidence for the combination and consistent supply of each component.

Coya depends on licensed patents and know-how. Breach, failure to meet development diligence, nonpayment, insolvency, or unsuccessful patent defense could terminate or narrow material rights. Houston Methodist can terminate under specified conditions, including failure to be actively developing or commercializing after the contractual period. Patent claims may be challenged or bypassed, and freedom-to-operate disputes can consume scarce capital.

Privacy, cybersecurity, health-data, anti-kickback, false-claims, healthcare-pricing, and promotional rules become more important as trials and commercialization progress. The company reported no material pending litigation at the cutoff. The higher-probability legal exposure is regulatory delay or loss of licensed rights, whose economic severity can exceed a fine because either can eliminate the lead asset.

Conclusion, Uncertainties and Disconfirming Evidence

Coya is an early clinical-development organization, not a profitable therapeutics franchise. It creates potential value by combining Treg-enhancing biology with a second immunomodulatory mechanism and using a partner to fund and commercialize major ALS territories. It can retain value through milestone and royalty rights, retained indications and territories, and any programs built around COYA 301. Whether that value exists depends first on controlled clinical efficacy and safety.

The evidence base is unusually limited: only four annual filings, beginning with fiscal 2022, are available, and none covers a completed controlled Phase 2 trial, pivotal development, approval, or commercial sale. This limitation is prominent because apparent strategic consistency over four filings is not evidence of through-cycle execution. Contrary evidence includes repeated financing, rising losses, reliance on one mechanistic backbone, upstream royalty burdens, partner control, and the FDA's earlier request for additional non-clinical data.

Adverse scenarios include ALSTARS failing efficacy or safety, slow enrollment, inconsistent manufacturing, loss of licensed rights, a Dr. Reddy's dispute, competing ALS data that changes the standard of care, and unavailable equity financing. The thesis is invalidated if randomized data do not confirm a clinically meaningful benefit; if the combination cannot be manufactured reproducibly; if partner and licensor claims leave inadequate residual economics; or if dilution grows faster than probability-adjusted program value. Cash into 2027 provides time for evidence, not proof of resilience through approval. The decisive fact will be rigorous clinical data, not collaboration revenue, biomarkers alone, or the number of named indications.

Business quality does not by itself establish investment attractiveness; valuation depends on the price paid and the expectations embedded in it.